SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around ongoing development and utilities, including staking and play-to-earn games, while highlighting its resilience as a long-term project. Community members are excited about upcoming burns and the potential for significant growth. The focus remains on building a strong foundation and achieving new all-time highs.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as traders anticipate the CPI release, with community members discussing potential market reactions and hedging strategies. Talk of terminated trade negotiations with Canada and their potential impact are circulating. Overall market sentiment seems cautiously bullish, with some bracing for volatility.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending due to a lowered Q1 revenue outlook, despite reaffirming strong full-year guidance and highlighting over $12 billion in new design wins for Q2 delivery. While some investors express frustration with management's forecasting, others view the dip as a buying opportunity, citing robust demand for AI solutions and confidence in long-term growth. Community discussions center on the significance of the delayed revenue and the potential for a rebound driven by strong Q2 performance.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

$AVNT is trending as the community discusses its recent price action and potential.  Traders are actively debating its volatility, entry points, and whether it can sustain its upward momentum.  Some believe its association with Coinbase and its position as a perp dex could drive future growth.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

B All In ($BALLIN) is gaining attention, with community members highlighting its availability on Phantom Wallet and touting potential gains. The conversation centers around the idea of a "balling" lifestyle and the opportunity for early entry. However, some users are also expressing skepticism, labeling it a scam.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid discussions about potential market manipulation and its seemingly unstoppable upward momentum, with community members debating whether a pullback is due. Speculation is high around upcoming CPI data and its potential impact, while some traders point to a disconnect between market performance and underlying fundamentals. Talk of a Trump-Xi meeting is also influencing sentiment.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF ($DIA) is trending due to renewed US-China trade tensions following President Trump's threat of increased tariffs, sparking market volatility and a sell-off. Community discussions revolve around the potential economic impact and whether this is a buying opportunity or the start of a larger correction. Investors are also monitoring upcoming earnings reports and potential shifts in Federal Reserve policy in response to these developments.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. It also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment offers products and services sold for applications within the data center, communication networks, and commercial and industrial markets in North America and Latin America. The Asia Pacific segment includes products and services sold for applications within the data center, communication networks, and commercial or industrial markets throughout Greater China, Australia and New Zealand, Southeast Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Columbus, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv is trending due to a combination of strong Q3 earnings, raised guidance, and positive analyst ratings, all driven by the increasing demand for AI infrastructure and data centers. The community is discussing the company's growth potential, strategic acquisitions, and its partnership with NVIDIA. Some investors express frustration with price action, while others remain bullish on the long-term prospects of Vertiv in the AI space.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors discuss the potential impact of AI developments and infrastructure investments, including a new data center project. Community members are weighing the stock's valuation and growth prospects ahead of upcoming earnings, with some anticipating a significant move. Discussions also involve technical analysis, potential partnerships, and the competitive landscape in the AI sector.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following its latest earnings report, which beat expectations and highlighted the company's focus on AI and foundry services. The community is discussing the potential for a significant rise, with some targeting $50 and beyond, driven by renewed confidence in Intel's growth prospects. Investors are also considering Intel's strategic importance and the impact of government support for domestic semiconductor manufacturing.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

Oncobiologics (OTLK) delivered earnings and revenue surprises of -4.76% and -40.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) Q2 Earnings Top Estimates

Kamada (KMDA) delivered earnings and revenue surprises of +44.44% and -0.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates

Coya Therapeutics, Inc. (COYA) delivered earnings and revenue surprises of -63.64% and -96.10%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -2.33% and -84.39%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

Beam Therapeutics (BEAM) delivered earnings and revenue surprises of +3.85% and -38.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Deutsche Bank bearish on European pharma stocks into Q2 amid political headwinds

Investing.com -- Deutsche Bank has made several rating and target price adjustments across the European pharmaceuticals space ahead of second-quarter earnings, flagging continued weakness in the sector and potential opportunities in select names.

The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move that removes a key policy tailwind for vaccine developers, including Moderna, Novavax, CureVac, and Traws Pharma.The CDC reportedly deactivated its response last week and will now track bird flu alongside seasonal influenza, updating human monitoring data monthly, Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-07/bird-flu-emergency-response-ends-in-us-as-infections-decline">reported</a>.&nbsp;Animal transmission data will no longer be published, the agency said. Washington and California, two of the most affected states, have also scaled back efforts.&nbsp;California ended its emergency declaration in April, while Washington is downsizing its public health response. The U.S. Department of Health and Human Services stated that the CDC’s transition reflects a return to regular program operations.&nbsp;During the response, 375 CDC staff had been assigned to the outbreak, the agency added.The CDC’s move comes amid broader federal cutbacks. Earlier this year, HHS scrapped a $766 million deal with Moderna for developing mRNA bird flu vaccines.Public health officials said a decline in surveillance would make it harder to spot the next outbreak.&nbsp; “We are letting our guard down,” said Michael Kinch, an infectious disease expert at Stony Brook University.In January, heightened bird flu fears had boosted attention on pandemic-preparedness companies.&nbsp;The U.S. reported its first human death from H5N1 in Louisiana and awarded $306 million for avian flu response, including $176 million to&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna</a> for its mRNA-1018 vaccine candidate.<a href="https://stocktwits.com/symbol/NVAX">Novavax</a> had been advancing pre-clinical H5N1 vaccine research, while Germany’s&nbsp;<a href="https://stocktwits.com/symbol/CVAC">CureVac</a> partnered with&nbsp;<a href="https://stocktwits.com/symbol/GSK">GlaxoSmithKline</a> on another bird flu shot.&nbsp;Traws Pharma, which is developing a one-dose antiviral therapy called tivoxavir marboxil, disclosed promising preclinical results in December 2024 and plans a Phase 2 trial this year.Bird flu has infected at least 70 people in the U.S. since the start of the outbreak, mostly agricultural workers. While most cases have been mild, one fatality was recorded in January. The virus remains a concern in migratory birds and cattle.Retail sentiment on Stocktwits was mixed across vaccine makers: ‘bullish’ for Moderna and GSK, ‘neutral’ for Novavax, and ‘bearish’ for CureVac. Meanwhile, message volume was ‘high’ for GSK, ‘normal’ for Moderna and Novavax, and ‘extremely low’ for CureVac.Year to date, Moderna shares are down 28.8%, Novavax has fallen 22.9%, while CureVac has gained 56.8%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma

The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.

Equity

CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech

Germany-based biotechnology firm BioNTech SE (BNTX) on Thursday said that it intends to acquire its peer CureVac (CVAC) in an all-stock transaction. CVAC stock shot up by about 32% in pre-market trading.Under the terms of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/12/3098162/0/en/BioNTech-Announces-Strategic-Transaction-to-Acquire-CureVac-in-Public-Exchange-Offer.html">deal</a>, each CureVac share will be exchanged for approximately $5.46 in BioNTech American depositary shares, resulting in an implied aggregate equity value for CureVac of roughly $1.25 billion.BioNTech also stated that the purchase consideration is subject to a collar mechanism. If the 10-day volume-weighted average price of BioNTech ADS shortly before the closing of the offer exceeds $126.55, the exchange ratio would be 0.04318, and if the price is lower than $84.37, the exchange ratio would be 0.06476.Upon closing of the transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech.BioNTech will own 100% of CureVac and its subsidiaries, and it will integrate CureVac’s research and manufacturing site in Tübingen.The companies stated that the acquisition will create long-term value for shareholders of both companies and will build on BioNTech’s track record in messenger ribonucleic acid (mRNA) commercialization, including its mRNA-based COVID-19 vaccine developed in collaboration with Pfizer Inc (PFE).CureVac is developing a class of medicines in oncology and infectious diseases based on mRNA. BioNTech said that the transaction will strengthen the research, development, manufacturing, and commercialization of mRNA-based cancer immunotherapy candidates.The transaction is expected to close in 2025, subject to the completion of customary closing conditions and receipt of regulatory approvals.On Stocktwits, retail sentiment around CureVac jumped from ‘bearish’ to ‘bullish’ over the past 24 hours while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_12_at_8_42_07_AM_png_e0cc4dfb95.webp" alt="CVAC's Sentiment Meter and Message Volume as of 8:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits" width="628" height="67"><figcaption>CVAC's Sentiment Meter and Message Volume as of 8:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user, who claims to hold CureVac shares, expressed disappointment, opining that they could have gotten a better deal.<stembedurl>https://stocktwits.com/Jbjb90/message/617662210</stembedurl>Meanwhile, retail sentiment around BioNTech rose from ‘neutral’ to ‘bullish’ over the past 24 hours while message volume fell from ‘normal’ to ‘low’ levels.<figure class="image"><img style="aspect-ratio:629/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_12_at_8_44_46_AM_png_29640c1cdc.webp" alt="BNTX's Sentiment Meter and Message Volume as of 8:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits" width="629" height="60"><figcaption>BNTX's Sentiment Meter and Message Volume as of 8:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said the deal might lead to a “breakthrough” in cancer treatment.<stembedurl>https://stocktwits.com/quinny2021/message/617661886</stembedurl><a href="https://stocktwits.com/symbol/BNTX">BNTX</a> is trading 1% higher in pre-market.While BNTX shares are down by about 9% this year, <a href="https://stocktwits.com/symbol/CVAC">CVAC shares</a> are up by about 18%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/synopsys-restarts-partial-services-in-china-amid-us-export-curbs/chlXDS8Rb6s">Synopsys Reportedly Restarts Partial Services In China Amid US Export Curbs, But Retail Remains Skeptical</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioNTech logo is displayed on a smartphone screen. (Photo illustration by Cheng Xin/Getty Images)

BioNTech To Acquire CureVac In All-Stock Deal Valued At $1.25B: Retail Sees Breakthrough In Cancer Treatment

Under the terms of the deal, each CureVac share will be exchanged for approximately $5.46 in BioNTech American depositary shares.

CureVac stock soars about 30% after BioNTech agrees to acquire co 

Investing.com -- CureVac NV (NASDAQ:CVAC) stock soared 29.5% on Thursday pre-market trading after German biotech firm BioNTech SE (NASDAQ:BNTX) said it would acquire the company for approximately $1.25 billion.

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

CVAC
CureVac N.V.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CVAC News

CVACCureVac N.V.